India’s Ingenuously developed COVID-19 Vaccine, Covaxin is all set to enter the third phase. The Drug Controller General of India (DGCA) recently gave permission for the third phase trial on 26,000 participants in 25 centers across the country.
The tests will be carried out in various hospitals in major cities. Willing Symptomatic patients with confirmed CT scans and chest X-rays will be given the vaccine dose. As a part of the trial, two doses will be imparted – 0.5 ml on day zero and day 28.
Bharat Biotech based in Hyderabad is developing the vaccine and Sai Prasad, executive director of the company says that the vaccine is likely to be out only in June 2021, if everything goes as per the plan. Across the globe, there are 42.2 Million confirmed Corona cases with 1.14 Million deaths.
In India, there are 7.81 Million cases with 118K deaths so far making it one of the worst-affected countries across the globe.
